AC Immune SA (ACIU) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Phibro Animal Health Corp.

Lexicon Pharmaceuticals, Inc.

Ovid Therapeutics, Inc.

Vanda Pharmaceuticals, Inc.

AC Immune SA

Compass Therapeutics, Inc.

Fulcrum Therapeutics, Inc.

Inozyme Pharma, Inc.

Atea Pharmaceuticals, Inc.

Third Harmonic Bio, Inc.

Acumen Pharmaceuticals, Inc.

Why is AC Immune SA ?

With a fall in Net Sales of -80.58%, the company declared Very Negative results in Jun 25

The company has declared negative results in Mar 25 after 2 consecutive negative quarters
NET SALES(9M) At USD 3.98 MM has Grown at -77.19%
INTEREST(HY) At USD 0.12 MM has Grown at 53.12%
ROCE(HY) Lowest at -50.57%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -14.96%, its profits have risen by 5.9%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -14.96% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is AC Immune SA for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

AC Immune SA

-10.28%

-0.50

71.47%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-7.42%

EBIT Growth (5y)

-181.27%

EBIT to Interest (avg)

-69.76

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.53

Sales to Capital Employed (avg)

0.16

Tax Ratio

0.01%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

29.34%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.00

EV to EBIT

-0.89

EV to EBITDA

-0.93

EV to Capital Employed

-0.91

EV to Sales

1.57

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-54.12%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

NET SALES(HY)

At USD 2.68 MM has Grown at 253.16%

NET PROFIT(HY)

Higher at USD -46.82 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -163.51 %

DEBTORS TURNOVER RATIO(HY)

Highest at 15.15 times

-22What is not working for the Company

NET SALES(9M)

At USD 3.98 MM has Grown at -77.19%

INTEREST(HY)

At USD 0.12 MM has Grown at 53.12%

ROCE(HY)

Lowest at -50.57%

OPERATING PROFIT(Q)

Lowest at USD -22.75 MM

PRE-TAX PROFIT(Q)

Lowest at USD -25.65 MM

NET PROFIT(Q)

Lowest at USD -25.65 MM

EPS(Q)

Lowest at USD -0.25

Here's what is working for AC Immune SA

Net Sales

At USD 2.68 MM has Grown at 253.16%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Debt-Equity Ratio

Lowest at -163.51 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 15.15 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for AC Immune SA

Pre-Tax Profit

At USD -25.65 MM has Fallen at -76.98%

over average net sales of the previous four periods of USD -14.5 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -25.65 MM has Fallen at -76.97%

over average net sales of the previous four periods of USD -14.5 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest

At USD 0.12 MM has Grown at 53.12%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Profit

Lowest at USD -22.75 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -25.65 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -25.65 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.25

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)